Medicare's 2003 weight-loss exclusion still blocks GLP-1 coverage

The rule that keeps Medicare from paying for weight-loss drugs is a line written into the Medicare Modernization Act of 2003, and it is still in force ^[2].

Section 1860D-2(e)(2)(A) of the Social Security Act excludes "agents when used for anorexia, weight loss, or weight gain" from Medicare Part D. The language was added during budget negotiations to control projected costs of the new drug benefit ^[2].

The exclusion does not turn on how well a drug works, whether the FDA approved it for obesity, a doctor's judgment of medical necessity, a patient's BMI, or whether obesity is causing other conditions Medicare covers ^[2]. It creates a binary: if the primary indication on the prescription is weight loss or obesity, Medicare cannot pay; if the primary indication is a covered condition such as type 2 diabetes or cardiovascular disease, Medicare can ^[2].

One molecule, two coverage answers

That is why semaglutide is covered as Ozempic for diabetes but not as Wegovy for obesity. The chemical is identical, and coverage turns on the FDA-approved indication and the diagnosis code on the prescription ^[2]. The exclusion also reaches older weight-loss drugs such as phentermine and orlistat, along with bariatric vitamins and meal replacements. Medicare guidance, rule changes and executive orders cannot override it; only Congress can ^[2].

Providers have worked around the gap by coding GLP-1 prescriptions under diabetes diagnoses. A 2024 Medicare Payment Advisory Commission analysis found that among Medicare beneficiaries filling GLP-1 prescriptions, 73 percent had a diabetes diagnosis code but only 58 percent had HbA1c lab values consistent with type 2 diabetes ^[2]. The workaround leaves out patients who have obesity but no diabetes or prediabetes, and reinforces the idea that obesity deserves treatment only once it progresses to metabolic disease ^[2].

The repeal effort

The Treat and Reduce Obesity Act, S. 1973, would strike the exclusion, allowing Part D and Medicare Advantage plans to include drugs such as Wegovy, Zepbound, Saxenda and Contrave on their formularies ^[2]. It would not require plans to cover them, cap copays, override prior authorization, extend coverage to compounded versions, or change Medicaid ^[2].

Introduced repeatedly since 2012, the bill has never received a floor vote in either chamber ^[2]. Its 2026 version has 26 Senate cosponsors, 14 Democrats and 12 Republicans, and 118 House cosponsors, the strongest support it has had ^[2].

Cost is the obstacle. The Congressional Budget Office estimated that Medicare coverage of anti-obesity medications would cost $35 billion over a nine-year period ^[1]. Another accounting of the same estimate puts it at $34.6 billion over 10 years ^[2].

Sen. Bill Cassidy (R-La.), a cosponsor and chair of the Senate health committee, said he would like to act on GLP-1s but was noncommittal on timing, saying his committee had other priorities ^[1]. Rep. Raul Ruiz (D-Calif.), a cosponsor, said: "Ultimately, what we need to do is we need to change the Medicare policy that views anti-obesity medications as just cosmetic weight loss" ^[1].

Why it matters for patients

For anyone on Medicare, whether a GLP-1 is covered depends on the diagnosis code attached to the prescription, not on the drug itself ^[2]. A patient with obesity and no diabetes or cardiovascular diagnosis falls outside Part D for that prescription ^[2].

Medicare Advantage is sometimes described as a workaround. About 40 plans nationwide, covering roughly 380,000 beneficiaries, offer some anti-obesity drug coverage as a supplemental benefit, concentrated in 11 states ^[2]. Those plans cap enrollment, require documented failure of at least two prior weight-loss interventions plus a BMI above 35 with a comorbidity or above 40 without one, and approve 15 to 30 percent of applicants, with coinsurance of 25 to 33 percent — about $300 to $400 a month for a drug with a $1,200 list price ^[2]. One estimate puts the number of patients covered this way below 60,000 ^[2].

Medicaid varies by state: 14 states cover anti-obesity drugs with prior authorization and 15 cover them only within BMI or comorbidity limits. The rest offer none, with one account listing 21 states in its state-by-state breakdown while its own summary says 22 ^[2].

Cash prices have fallen. Under agreements with manufacturers, the administration says it negotiated prices on most popular GLP-1s, which are typically not covered by insurance; costs listed on the TrumpRx site range from $149 to $299 a month, and some of those prices last only a limited time ^[1].

What happens next

The Centers for Medicare & Medicaid Services launched a voluntary demonstration this year that lets some Medicare and Medicaid beneficiaries get GLP-1s for obesity treatment ^[1]. The 2026 budget reconciliation process begins in May; if the obesity bill is attached to it, it would likely take effect in 2027, allowing CMS time to issue guidance to Part D plans ^[2]. President Donald Trump has pushed Congress to codify a "most favored nation" policy tying US drug prices to lower prices abroad; Congress has so far resisted ^[1].